Search Web Site
LABORATORY PROCEDURES FOR ANIMAL & HUMAN CELL LINES
REFERENCE NO: AHC/1998/2/2
TITLE: MASTER CELL BANKING AND QUALITY CONTROL FOR NEW DEPOSITS
After registration of the new deposit for inclusion into the collection and reception of the cell line, master cell banking and quality control tests are processed.
If all quality control tests yield to satisfactory results, the procedure is continued as described in AHC/1998/2/3.
If there is a failure of a quality control test, the depositor is informed by letter. Typically, quality control test failures may include the following:
- Master cell bank stocks of the new cell line are prepared and subjected to quality control as described in AHC/1998/3/2.1/1,
- Mycoplasma contamination
- Bacterial/fungal/yeast contamination
- Wrong species (by isoenzyme analysis)
- Absence of antibody secretion or incorrect class/subclass of antibody secretion, by hybridomas
In the first instance, alternative cell line stocks are requested from the depositor who may circumvent the problem.
3.1 If the depositor is unable to supply the alternative cell line stocks, the accession process is halted. Cell line stocks are retained in liquid nitrogen storage
3.2 If a customer request the cell line, an eradication procedure will take place, in order to supply the cell. If the eradication procedure is successful, the procedure is continued as described in AHC/1998/2/3
Guidelines prepared for CABRI by CERDIC, DSMZ, ECACC, INRC, November 1998
Page layout by CERDIC
Copyright CABRI, 1998
© The CABRI Consortium 1999-2013.
This work cannot be reproduced in whole or in part without the express
written permission of the CABRI consortium.
Site maintained by Paolo Romano. Last revised on April 2013.